Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry

Autor:	Lourdes Escoda, Manuel Barrios, Isabel Krsnik, Olga Salamero, Fernando Ramos, Susana Vives, Jalanta Oleksiuk, Manuel Pérez-Encinas, Félix Manso, David Martínez-Cuadrón, José González-Campos, Marta Sobas, Cristina Gil, Pau Montesinos, Andrés Novo, Celina Benavente, Josefina Serrano, Javier de la Serna, Salut Brunet, Miguel A. Sanz, Jordi Esteve, Mari-Luz Amigo, Pethema, Raimundo García-Boyero, J. Arias, Palg Groups
Přispěvatelé:	European Commission, Centro de Investigación Biomédica en Red Cáncer (España)
Rok vydání:	2019
Předmět:	Acute promyelocytic leukemia Male Cancer Research Pediatrics medicine.medical_specialty Population Tretinoin AIDA Regimen Cohort Studies 03 medical and health sciences 0302 clinical medicine Leukemia Promyelocytic Acute Induction Death Antineoplastic Combined Chemotherapy Protocols Medicine Humans Elderly APL APL prognostic factors Registries education neoplasms Aged Aged 80 and over education.field_of_study business.industry Remission Induction Complete remission Hematology medicine.disease Induction mortality in APL Survival Rate Treatment Outcome Oncology 030220 oncology & carcinogenesis APL real life outcomes Treatment strategy Female Neoplasm Recurrence Local business Idarubicin 030215 immunology Follow-Up Studies
Zdroj:	Digital.CSIC. Repositorio Institucional del CSIC instname
ISSN:	1029-2403
Popis:	PETHEMA And PALG Groups. Acute promyelocytic leukemia is infrequent among patients aged ≥75 years old, a population that is rarely eligible for clinical protocols. This study aims to analyze the treatment strategies and clinical outcomes of very old APL patients reported to the international PETHEMA registry. Between 1997 and 2017, among 2501 APL cases registered 120 were ≥75 years old. Treatment approaches were: AIDA regimen, 79 patients; ATRA alone, 23; 16, supportive care (SC) and 2, other strategies. Patients treated with AIDA were younger, had better ECOG and lower leukocytes. Complete remission (CR) was achieved in 65% of AIDA-group vs. 45% in the ATRA-group, being infections followed by bleeding the most frequent causes of induction death. Patients in CR after AIDA showed 3-year DFS of 73%. Our real-life series of very old APL patients provides a reference basis for future treatment strategies aiming to improve clinical outcomes in this challenging population. This work was partially financed with FEDER Funds (CIBERONC (CB16/12/00284)).
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8afacf4a635cc4f34e005bf2239648d https://pubmed.ncbi.nlm.nih.gov/31068052 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.